CMB.TECH 15.420 € (+0,13 %)     AB INBEV 73.280 € (+0,41 %)     D'IETEREN GROUP 180.700 € (+2,09 %)     TINC 10.440 € (+0,97 %)     KBC 116.550 € (+2,60 %)     COLRUYT 35.880 € (+1,82 %)     ELIA GROUP 129.700 € (+1,17 %)     PROXIMUS 6.185 € (+2,06 %)     UMICORE 18.680 € (+5,18 %)     GBL 78.000 € (+0,58 %)     LOTUS BAKERIES 13 840.000 € (+0,73 %)     ARGENX SE 808.000 € (+2,43 %)     TESSENDERLO 17.630 € (+1,44 %)     AEDIFICA 64.850 € (+0,62 %)     DECEUNINCK 2.460 € (+2,29 %)     AGEAS 77.500 € (+2,24 %)     KBC ANCORA 95.100 € (+3,26 %)     SOFINA 277.400 € (+0,51 %)     NYXOAH 0.750 € (-3,85 %)     SOLVAY 23.780 € (+1,36 %)     EVS 18.260 € (+1,44 %)     ACKERMANS V.HAAREN 271.400 € (+2,03 %)     DEME GROUP 173.800 € (+2,72 %)     MELEXIS 56.150 € (+0,27 %)     WDP 19.160 € (+0,16 %)     AZELIS GROUP 11.920 € (-0,58 %)     SYENSQO 77.300 € (+0,65 %)     JENSEN-GROUP 72.800 € (-0,55 %)     TITAN S.A. 48.740 € (+1,58 %)     ONWARD MEDICAL 1.910 € (+1,06 %)     ONTEX GROUP 1.546 € (-0,77 %)     UCB 278.100 € (+0,58 %)     BREDERODE 100.200 € (+0,20 %)     XIOR 25.100 € (+0,40 %)     KINEPOLIS GROUP 49.400 € (+1,44 %)     FAGRON 23.650 € (+0,85 %)     BIOTALYS 1.950 € (+1,56 %)     CELYAD ONCOLOGY 0.180 € (-8,16 %)     CARE PROPERTY INV. 12.540 € (+1,13 %)     CENERGY 21.880 € (-0,64 %)     RECTICEL 12.320 € (+1,15 %)     MONTEA 67.000 € (+0,15 %)     BEKAERT 41.100 € (+0,24 %)     GIMV 49.300 € (+0,10 %)     BARCO 6.515 € (+1,40 %)     INCLUSIO SA/NV 15.200 € (+0,33 %)     EXMAR 11.250 € (-1,32 %)     VIOHALCO 15.200 € (+2,01 %)     ECONOCOM GROUP 1.555 € (+3,67 %)     TUBIZE-FIN 228.800 € (+0,62 %)     VGP 63.700 € (+0,63 %)     QUESTFOR GR-PRICAF 2.618 € (-1,60 %)     CAMPINE 181.000 € (+6,47 %)     ASCENCIO 53.900 € (+0,75 %)     HOME INVEST BE. 17.900 € (+1,70 %)     WERELDHAVE BELGIUM 50.400 € (+0,80 %)     HYBRID SOFTWARE GR 3.820 € (+3,24 %)     SHURGARD 24.950 € (+0,81 %)     SOLVAC 84.500 € (+1,81 %)     RETAIL ESTATES 62.300 € (0,00 %)  
   FDJ UNITED 21.860 € (+0,60 %)     AYVENS 9.210 € (+2,05 %)     CVC CAPITAL 14.660 € (+2,73 %)     STIF 19.580 € (-0,46 %)     MINT 4.280 € (-1,83 %)     PUBLICIS GROUPE SA 102.400 € (+1,24 %)     L'OREAL 436.050 € (+0,77 %)     BUREAU VERITAS 29.210 € (+0,21 %)     TOTALENERGIES 82.570 € (-0,17 %)     VOLTALIA 3.970 € (+7,30 %)     BIOPHYTIS 0.032 € (+24,03 %)     GALP ENERGIA-NOM 20.180 € (+0,85 %)     KERING 186.280 € (+3,35 %)     SHELL PLC 46.300 € (-0,46 %)     TECHNIP ENERGIES 33.520 € (+0,72 %)     LVMH 407.000 € (+1,37 %)     ROCTOOL 1.365 € (+36,50 %)     SANOFI 81.830 € (+1,05 %)     UNILEVER 57.970 € (-0,70 %)     METROPOLE TV 11.300 € (+11,66 %)     VIRIDIEN 102.400 € (+11,67 %)     BNP PARIBAS ACT.A 91.250 € (+4,15 %)     CBO TERRITORIA 3.690 € (+0,27 %)     ASML HOLDING 1 379.800 € (-0,38 %)     CARREFOUR 13.310 € (+1,80 %)     THALES 225.900 € (-3,05 %)     ING GROEP N.V. 28.860 € (+4,13 %)     SES 4.106 € (-0,68 %)     ALTAREA 73.500 € (+1,80 %)     ALTEN 89.000 € (+1,95 %)     SOCIETE GENERALE 64.320 € (+4,50 %)     ADYEN 846.000 € (+2,20 %)     CAPGEMINI 126.500 € (+1,04 %)     HEINEKEN 81.040 € (+0,25 %)     GOLD BY GOLD 4.520 € (-1,31 %)     STMICROELECTRONICS 43.385 € (+0,66 %)     AHOLD DEL 33.410 € (+3,89 %)     WOLTERS KLUWER 88.980 € (+4,14 %)     STELLANTIS NV 4.040 € (-1,08 %)     PAULIC MEUNERIE 1.135 € (-0,44 %)     AIRBUS 195.000 € (+0,87 %)     ONE EXPERIENCE 0.260 € (-2,63 %)     AIR FRANCE -KLM 11.235 € (+3,50 %)     CHRISTIAN DIOR 440.600 € (+1,24 %)     B.COM.PORTUGUES 1.104 € (+5,34 %)     VALLOUREC 18.855 € (+2,14 %)     ATEME 11.500 € (0,00 %)     BAM GROEP KON 12.970 € (+2,05 %)     ADP 116.200 € (+1,66 %)     SAFRAN 290.700 € (+2,00 %)     2CRSI 17.360 € (+4,64 %)     KAUFMAN ET BROAD 19.720 € (+0,41 %)     SOITEC 120.650 € (-3,29 %)     PHILIPS KON 26.070 € (+1,44 %)     ALSTOM 11.235 € (+0,99 %)     IMCD 103.550 € (-0,72 %)     BIOMERIEUX 94.850 € (+0,11 %)     AALBERTS NV 41.880 € (-1,09 %)     THE NAVIGATOR COMP 3.030 € (+1,27 %)     MAGNUM 17.380 € (-0,31 %)  
News Réglementées
14/10/2026 17:06

innoscripta SE Expands Customer Base / Clusterix Now Used in Additional European Markets

EQS-News: innoscripta SE / Key word(s): Miscellaneous
innoscripta SE Expands Customer Base / Clusterix Now Used in Additional European Markets

14.10.2026 / 17:06 CET/CEST
The issuer is solely responsible for the content of this announcement.


innoscripta SE Expands Customer Base / Clusterix Now Used in Additional European Markets

  • Strong international growth continues: New customers acquired across numerous European countries
  • R&D platform Clusterix now established in 14 countries

Tutzing, October 14, 2026 – innoscripta SE (ISIN: DE000A40QVM8, the “Company”) has acquired new customers in several European countries during the current financial year as part of its growth strategy.

In Poland, the Company has signed contracts with businesses across various industries, including automotive suppliers, telecommunications and household goods, that benefit from the Polish R&D tax relief scheme. innoscripta has also gained customers in other European markets, including Romania, Denmark, Finland, Switzerland, Spain, Portugal, Slovakia and the Netherlands.

Together with Germany and its existing customer relationships in Austria, France, the United Kingdom and the United States, innoscripta now serves customers in 14 countries, each with its own regulatory framework for R&D tax incentives, through its digital platform Clusterix.

One Documentation Framework, Multiple Countries

Almost every European country offers tax incentives for research and development, but each has its own instruments and regulatory requirements. To qualify for these incentives, companies must provide supporting documentation demonstrating which employees worked on which projects, when they performed the work and how much time they spent.

innoscripta's Clusterix platform addresses these documentation requirements efficiently. It enables the ongoing recording of project hours by employee, day and project, supported by system-based plausibility checks and monthly approval by the project managers responsible, all recorded transparently.

This is a particularly important advantage for internationally operating corporate groups: companies with R&D facilities in multiple countries can use a consistent documentation framework, regardless of the specific tax incentive scheme applicable in each jurisdiction.

Poland, in particular, represents an attractive growth market for innoscripta. Under the Polish R&D tax relief scheme (ulga B+R), eligible R&D personnel costs can be deducted at a rate of 200%. As in Germany, the Polish Corporate Income Tax Act provides that personnel costs qualify only in proportion to the time actually spent on research and development by each employee during the respective month.

In addition, Polish law explicitly requires R&D costs to be recorded separately in the company's accounting records. Clusterix's monthly, employee-level time tracking enables the Company's customers to meet these demanding documentation requirements, making Poland a market with attractive growth potential.

With its Clusterix platform, innoscripta can leverage synergies and reach new customers across a wide range of European markets.

Sebastian Schwertlein, COO of innoscripta SE, commented:

“We developed Clusterix for the most demanding market we knew: Germany. The fact that customers from different industries in Poland, the Netherlands and Finland are now turning to us demonstrates that this documentation framework works across borders and is fully scalable wherever R&D incentives depend on reliable supporting evidence.

Fourteen countries are not an endpoint for us. This is clear evidence that our platform delivers value to businesses across Europe.”

 

About innoscripta

innoscripta SE offers Clusterix, a scalable software platform for the structured organization and management of research and development activities. Companies use Clusterix to efficiently manage innovation projects, digitize internal processes, and make their R&D activities transparent and scalable.

 

Investor Relations Contact

innoscripta SE

Max Hunger

ir@innoscripta.de

 

Press contact

edicto GmbH

Ralf Droz / Svenja Liebig

+49 69 905505 56

innoscripta@edicto.de

 



14.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language:English
Company:innoscripta SE
Bahnhofstraße 17
82327 Tutzing
Germany
Phone:+4989255553509
E-mail:info@innoscripta.com
Internet:https://www.innoscripta.com
ISIN:DE000A40QVM8
WKN:A40QVM
Listed:Regulated Unofficial Market in Frankfurt (Scale)
LEI Code:894500BA6B025ZEF0T83
EQS News ID:2416008

 
End of NewsEQS News Service

2416008  14.10.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière